LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Transition Therapeutics, Inc. ("Transition") (TSX: TTH) (NASDAQ: TTHI), a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include:
  • ELND005: small molecule drug to enter Phase 3 for the treatment of Alzheimer's disease
  • TT401/TT402: long-acting GLP-1 dual agonists for type 2 diabetes that provide glycemic control, weight management, improved lipid profile and better GI tolerability
  • TT301/TT302: novel orally bioavailable aminopyridizines for rheumatoid arthritis, that inhibit multiple pro-inflammatory cytokines and chemokines

“Transition’s strong record of executing against their business model is quite impressive,” said Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. “They have a strong cash position, no debt, and their lead drug, ELND005, is poised to enter Phase 3 for Alzheimer’s disease in partnership with Elan, who are responsible for all Phase 3 costs, leaving only upside potential for Transition. With ELND005’s disease-modifying mechanism and oral dosing advantage, it is positioned to compete successfully in the burgeoning Alzheimer’s disease space, a market with potential to exceed $10 Billion in annual worldwide sales. Transition’s earlier stage pipeline includes diabetes compounds TT401/402 which have a highly compelling profile and TT301/TT302, which are positioned for success in rheumatoid arthritis as oral successors to the current biologic therapies.”

In a 53-page Initiation Report by LifeSci Advisors, the preclinical and clinical achievements of ELND005 to date are presented, as is a detailed analysis favoring use of the drug in early stage Alzheimer’s patients. The safety and pharmacokinetics of ELND005 has been evaluated in a total of nine Phase 1 studies in 161 healthy volunteers, including healthy elderly subjects. A recently completed Phase 2 study called AD201 was a randomized, double-blind, placebo-controlled, dose-ranging study for ELND005 in patients with mild to moderate Alzheimer’s disease. For AD201, mild to moderate patients, aged 50-85 years were randomized, and an open label extension of the study called AD251 is ongoing. The report also examines the rapidly changing landscape for drug development in the growing Alzheimer’s disease space, including the ongoing paradigm shift within the field regarding increasing use of biomarkers and the evolving perspective on selection of inclusion criteria and endpoints for clinical studies. Also emphasized is the importance of providing disease modifying therapy to patients at earlier stages of the disease, where the potential for patient benefit is greatest.

Transition’s diabetes compounds TT401/402, brought in through a partnership with Eli Lilly, simultaneously address both glycemic control and weight reduction. TT401/TT402 are long-acting GLP-1 dual agonists that address multiple unmet medical needs by offering glycemic control, superior weight management and improved lipid profile, plus better GI tolerability as compared to current GLP-1 drugs. Furthermore, these compounds are being developed as once weekly administrations, a major dosing advantage over currently approved injectable GLP-1 therapies that are dosing once or twice daily. Phase 1-enabling preclinical studies are currently underway, with initiation of Phase 1 targeted for 4Q 2011. Also included in the report is a complete background of Transition’s programs, preclinical and clinical history to date, upcoming expected milestones, product positioning in the markets, and associated risks.

Dr. McDonald’s full Initiation Report is available to download at no cost at the LifeSci Advisors website, In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.

The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.

About LifeSci Advisors:

LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company’s website,

Important Disclosures:

The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website,, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.

Forward-looking statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.

Copyright Business Wire 2010